Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trimix is a multi-action ophthalmic formulation developed by Off Health Italia, designed to treat dry eye disease (DED). It combines viscosity-enhancing hyaluronic acid, trehalose, and cationic liposomes comprising stearylamine and phospholipids. This combination aims to disrupt the DED vicious cycle by improving tear film stability, providing mechanical protection and lubrication to ocular surface cells, protecting against desiccation and oxidative damage, accelerating corneal healing, reducing inflammation, and restoring osmotic balance. The cationic liposomes specifically replenish and stabilize the lipid layer of the tear film, enhancing its thickness and spreading on the ocular surface.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Trimix.